Paper7842289
Induction of lymphokine-activated killing with reduced secretion of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma by interleukin-2 analogs.
Heaton KM and 2 others. Ann Surg Oncol, 1994. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. Induction of lymphokine-activated killing with reduced secretion of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma by interleukin-2 analogs. Papers, record 7842289. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7842289
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Induction of lymphokine-activated killing with reduced secretion of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma by interleukin-2 analogs.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cytotoxicity, Immunologic | Major topic |
| Interferon-gamma | Major topic |
| Interleukin-1 | Major topic |
| Interleukin-2 | Major topic |
| Killer Cells, Lymphokine-Activated | Major topic |
| Tumor Necrosis Factor-alpha | Major topic |
| Cytotoxicity Tests, Immunologic | |
| Humans | |
| Immunotherapy, Adoptive | |
| Leukocytes, Mononuclear | |
| Neoplasms | |
| Recombinant Proteins |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| 5 T32 CA09500-04 | NCI NIH HHS | United States | T32CA095000 | PubMed | NIH RePORTER |
| CA45445 | NCI NIH HHS | United States | PubMed | PubMed |
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1760811 | Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity. | Cancer Immunol Immunother | 1991 | https://conductscience.org/library/papers/1760811 | PubMed |
| 2 | 2052547 | Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor. | Proc Natl Acad Sci U S A | 1991 | https://conductscience.org/library/papers/2052547 | PubMed |
| 3 | 2679456 | Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. | Ann Surg | 1989 | https://conductscience.org/library/papers/2679456 | PubMed |
| 4 | 6403654 | Ia expression by vascular endothelium is inducible by activated T cells and by human gamma interferon. | J Exp Med | 1983 | https://conductscience.org/library/papers/6403654 | PubMed |
| 5 | 2066765 | Interleukin-2 toxicity. | J Clin Oncol | 1991 | https://conductscience.org/library/papers/2066765 | PubMed |
| 6 | 3495302 | Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. | Blood | 1987 | https://conductscience.org/library/papers/3495302 | PubMed |
| 7 | 1858030 | Pentoxifylline inhibits interleukin-2-induced leukocyte-endothelial adherence and reduces systemic toxicity. | Surgery | 1991 | https://conductscience.org/library/papers/1858030 | PubMed |
| 8 | 1356627 | Interferon gamma but not tumor necrosis factor alpha decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells. | Cancer Immunol Immunother | 1992 | https://conductscience.org/library/papers/1356627 | PubMed |
| 9 | 2647913 | A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. | J Clin Oncol | 1989 | https://conductscience.org/library/papers/2647913 | PubMed |
| 10 | 3134297 | IL-1 and IFN-gamma increase vascular permeability. | Immunology | 1988 | https://conductscience.org/library/papers/3134297 | PubMed |
| 11 | 3258319 | Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. | J Clin Invest | 1988 | https://conductscience.org/library/papers/3258319 | PubMed |
| 12 | 3493433 | Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. | N Engl J Med | 1987 | https://conductscience.org/library/papers/3493433 | PubMed |
| 13 | 1596901 | Interleukin 2 acutely induces platelet and neutrophil-endothelial adherence and macromolecular leakage. | Cancer Res | 1992 | https://conductscience.org/library/papers/1596901 | PubMed |
| 14 | 6176669 | Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. | J Exp Med | 1982 | https://conductscience.org/library/papers/6176669 | PubMed |
| 15 | 1515427 | Reversible cardiomyopathy after high-dose interleukin-2 therapy. | J Immunother (1991) | 1992 | https://conductscience.org/library/papers/1515427 | PubMed |
| 16 | 3258039 | Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. | J Natl Cancer Inst | 1988 | https://conductscience.org/library/papers/3258039 | PubMed |
| 17 | 2788701 | Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity. | J Exp Med | 1989 | https://conductscience.org/library/papers/2788701 | PubMed |
| 18 | 3123071 | Functional differentiation of human lymphokine-activated killing (LAK) is distinct from expansion and involves dissimilar interleukin 2 receptors. | Cell Immunol | 1988 | https://conductscience.org/library/papers/3123071 | PubMed |
| 19 | 1375656 | Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes. | J Natl Cancer Inst | 1992 | https://conductscience.org/library/papers/1375656 | PubMed |
| 20 | 3129500 | Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells. | J Immunol | 1988 | https://conductscience.org/library/papers/3129500 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40201389 | Cytokine Couture: Designer IL2 Molecules for the Treatment of Disease. | Immunotargets Ther | 2025 | https://conductscience.org/library/papers/40201389 | PubMed |
| 37815596 | Immunotherapies landscape and associated inhibitors for the treatment of cervical cancer. | Med Oncol | 2023 | https://conductscience.org/library/papers/37815596 | PubMed |
| 35213635 | Human IL-2Rɑ subunit binding modulation of IL-2 through a decline in electrostatic interactions: A computational and experimental approach. | PLoS One | 2022 | https://conductscience.org/library/papers/35213635 | PubMed |
| 34553029 | Prognostic and therapeutic TILs of cervical cancer-Current advances and future perspectives. | Mol Ther Oncolytics | 2021 | https://conductscience.org/library/papers/34553029 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| IL1B | 3553 | PubTator's text mining | https://conductscience.org/library/genes/3553 | NCBI Gene |
| IL2 | 3558 | PubTator's text mining | https://conductscience.org/library/genes/3558 | NCBI Gene |
| IL2RB | 3560 | PubTator's text mining | https://conductscience.org/library/genes/3560 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7842289
GET https://conductscience.org/api/papers/v1/7842289/references?page=2